Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study

Creative Commons License

Kalincik T., Brown J. W. L. , Robertson N., Willis M., Scolding N., Rice C. M. , ...More

LANCET NEUROLOGY, vol.16, no.4, pp.271-281, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 16 Issue: 4
  • Publication Date: 2017
  • Doi Number: 10.1016/s1474-4422(17)30007-8
  • Title of Journal : LANCET NEUROLOGY
  • Page Numbers: pp.271-281


Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy relative to more potent immunotherapies is unknown. We compared the effectiveness of alemtuzumab with natalizumab, fingolimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to 5 years.